We are international
Donate
• IMF TV TEXT SIZE   
#Ask Dr. Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

01.28.16   Can myeloma progress after an autologous stem cell transplant (ASCT)?

In this week's video, Dr. Brian Durie the pros and cons of an autologous stem cell transplant (ASCT).

Bottom Line:

It is rare to become worse after ASCT, and its likely benefits need to be evaluated on a long-term basis.


01.21.16   Will any of the newly FDA-approved drugs be available for frontline therapy?

In this week's video, Dr. Brian Durie discusses if the newly FDA-approved drugs (Ninlaro, Emplicity, Darzalex) be available for frontline therapy?

Bottom Line:

When to use the new drugs requires a case-by-case discussion, with possible use in early disease stages.


01.14.16   What Should we know about FDA approval of Empliciti® (elotuzumab)?

In this week's video, Dr. Brian Durie discusses what patients and caregivers need to know on the recent approval of Empliciti® (elotuzumab).

Bottom Line:

Empliciti is a useful drug when used in combination with Rev/dex in a relapse setting.


01.07.16   What should we know about the FDA approval of Ninlaro® (ixazomib)?

In this week's video, Dr. Brian Durie discusses the recently FDA approved drug Ninlaro® (ixazomib).

Bottom Line:

Ninlaro is an important addition to the lineup of myeloma treatments.


12.17.15   What should we know about FDA approval of Darzalex® (daratumumab)?

In this week's video, Dr. Brian Durie discusses the first monoclonal antibody approved for myeloma treatment - Darzalex (daratumumab). 

Bottom  Line:

Darzalex is a useful drug that has some drawbacks in terms of testing


11.12.15   What is Ixazomib?

In this week's video, Dr. Brian Durie the new oral proteasome inhibitor ixazomib.

Bottom Line:
It will be very good for patients if ixazomib is as valuable as currently available drugs


11.05.15   Can DDT exposure cause myeloma?

In this week's video, Dr. Brian Durie answers the question if the insecticide DDT can cause myeloma?

Bottom Line:

We need to understand better how to prevent toxic exposure as another means of preventing myeloma


10.29.15   Can you help make sense of statistics?

In this week's video, Dr. Brian Durie helps make sense of the numbers and statistics in relation with your myeloma diagnosis and treatment.

Bottom Line:

The IMF will be a resource to help educate patients about statistics


10.22.15   What does it mean to be MRD-negative if you have high-risk 17p- myeloma?

In this week's video, Dr. Brian Durie discusses the implications of being MRD-negative if you have high-risk 17p- myeloma.

Bottom Line:

Testing will hopefully lead to improved therapies for patients with 17p- myeloma.


10.01.15   Do bone lesions regenerate?

In this week's video, Dr. Brian Durie answers the question do bone lesions regenerate.

Bottom Line:

Bones don't heal back to normal, but there are ways to recover functionality.


previous     next      view all